Key Developments: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

10.01USD
1 Apr 2015
Change (% chg)

$0.15 (+1.52%)
Prev Close
$9.86
Open
$9.82
Day's High
$10.04
Day's Low
$9.56
Volume
2,899,785
Avg. Vol
5,313,997
52-wk High
$16.87
52-wk Low
$2.45

Search Stocks

Latest Key Developments (Source: Significant Developments)

Achillion Pharmaceuticals Inc announces closing of public offering of common stock
Wednesday, 18 Feb 2015 04:30pm EST 

Achillion Pharmaceuticals Inc:Closes public offering of common stock.Sold 13,800,000 shares of its common stock in the offering at a price to the public of $10.25 per share, including the exercise in full by the underwriters of their option to purchase an additional 1,800,000 shares of common stock at the public offering price.Received net proceeds of about $132.7 mln, after deducting underwriting discounts and commissions and estimated offering expenses.Leerink Partners LLC and Deutsche Bank Securities Inc. acted as joint book-running managers, Wells Fargo Securities, LLC acted as lead manager, and JMP Securities LLC acted as co-manager for the offering.  Full Article

Achillion Pharmaceuticals Inc announces pricing of public offering of common stock
Wednesday, 11 Feb 2015 11:59pm EST 

Achillion Pharmaceuticals Inc:Announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $10.25 per share.All of the shares in the offering will be sold by Achillion.The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be about $115.3 million.The offering is expected to close on Feb. 18, 2015.Leerink Partners LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers, Wells Fargo Securities, LLC is acting as lead manager, and JMP Securities LLC is acting as co-manager for the offering.Achillion has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of its common stock on the same terms and conditions.The expected net proceeds to Achillion referenced above do not include any net proceeds that Achillion would receive if the underwriters exercise such option.  Full Article

Achillion Pharmaceuticals Inc announces proposed public offering of common stock
Tuesday, 10 Feb 2015 04:05pm EST 

Achillion Pharmaceuticals Inc:Commences underwritten public offering of 10,000,000 shares of its common stock.In connection with this offering, Achillion plans to grant the underwriters a 30-day option to purchase additional shares of its common stock.All of the shares in the offering will be sold by Achillion.Leerink Partners LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for the offering.Offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Full Article

Achillion Pharmaceuticals Inc achieves 100 pct SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102
Monday, 9 Feb 2015 06:30am EST 

Achillion Pharmaceuticals Inc:Updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients.Says primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after completion of therapy. One hundred percent of patients (12/12) in the six-week treatment duration arm achieved SVR12, which included patients with high baseline viral load.Says following the achievement of 100 pct SVR12 (12/12) in the eight-week cohort, the six-week treatment cohort was initiated.Says twelve weeks after the completion of therapy, 100 percent (12/12) achieved SVR12, independent of baseline viral load, gender, and IL28B status, in the six-week treatment arm.Says the combination of ACH-3102 and sofosbuvir was well-tolerated with no serious adverse events, no discontinuations due to adverse events, and no clinically significant laboratory or ECG abnormalities.  Full Article

Achillion granted U.S. patent for ACH-3102 and Structurally Related NS5A Inhibitors
Tuesday, 19 Aug 2014 04:05pm EDT 

Achillion Pharmaceuticals Inc:Announces that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds.  Full Article

Achillion Pharmaceuticals Inc achieves 100 pct sustained virologic response rate from an eight week phase 2 trial
Friday, 15 Aug 2014 06:59am EDT 

Achillion Pharmaceuticals Inc:Says interim results from ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection.Says of the 12 patients treated, 100 percent (n=12/12) remained HCV RNA undetectable four weeks after completing therapy (SVR4).Says based upon these results, 12 additional patients will begin treatment with six weeks of once daily ACH-3102 and sofosbuvir.Says ACH-3102 continues to demonstrate good safety and tolerability through three Phase 2 studies.Says primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after the completion of therapy\.Says Twelve patients completed eight weeks of treatment consisting of 50 mg of ACH-3102 and 400 mg of sofosbuvir administered once daily while observational patients received no drug during this phase of the trial.Says Ten of 12 patients receiving eight weeks of treatment had genotype 1a HCV with median HCV RNA at baseline of 7.22 log10(range 5.5 - 7.8 log10).Says no on-treatment viral breakthrough or post-treatment viral relapse has been observed to date.Says ACH-3102 and sofosbuvir were well tolerated with no significant adverse events, ECG findings, or lab abnormalities observed during treatment.  Full Article

Achillion Pharmaceuticals Inc announces initiation of ACH-3422 Dosing in HCV-Infected Patients and ability to resume Sovaprevir clinical program for treatment of Chronic HCV
Tuesday, 10 Jun 2014 06:05am EDT 

Achillion Pharmaceuticals Inc:Company has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days in patients with genotype 1 chronic hepatitis C viral infection (HCV) in its ongoing Phase 1 clinical trial.Proof-of-concept results from this trial are expected to be reported during the fall of 2014.FDA removed clinical hold to permit the conduct of therapeutic trials with a maximum of 200 mg once daily of sovaprevir in HCV patients and in single dose trials in healthy volunteers.Says but maintained a partial clinical hold for multiple dose studies that may be conducted in healthy volunteers, requiring prior review and approval of the protocol by FDA.Achillion expects to continue to work collaboratively with FDA on the continued clinical development of sovaprevir.  Full Article

Achillion Pharmaceuticals Inc gives FY 2014 net loss outlook above analysts' estimates
Friday, 7 Mar 2014 06:05am EST 

Achillion Pharmaceuticals Inc:Expects FY 2014 net loss per share to about $0.70 per share.FY 2014 EPS of ($0.81) - Thomson Reuters I/B/E/S.  Full Article

Pomerantz Law Firm Files Class Action Against Achillion Pharmaceuticals Inc and Certain Officers
Friday, 8 Nov 2013 04:33pm EST 

Pomerantz Grossman Hufford Dahlstrom & Gross LLP announced that it has filed a class action lawsuit against Achillion Pharmaceuticals Inc (Achillion or the Company) and certain of its officers. The class action, filed in United States District Court, District of Connecticut, and docketed under 13-cv-1479, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Achillion between April 21, 2012 and September 27, 2013 both dates inclusive (the Class Period). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects, including the safety and suitability of its premier investigative drug for the treatment of hepatitis, sovaprevir.  Full Article

Wolf Haldenstein Adler Freeman & Herz LLP Commences Class Action Lawsuit On Behalf Of Achillion Pharmaceuticals Inc. Investors
Thursday, 24 Oct 2013 04:12pm EDT 

Wolf Haldenstein Adler Freeman & Herz LLP announced that a class action lawsuit has been filed in the United States District Court, District of Connecticut, on behalf of all persons who purchased or otherwise acquired common stock of Achillion Pharmaceuticals, Inc. (Achillion or the Company) (NASDAQ GS:ACHN) between August 8, 2012 and September 30, 2013, inclusive (the Class Period), against the Company and certain of the Company`s officers (Defendants). The Complaint alleges that during the Class Period, Achillion engaged in a fraudulent scheme to artificially inflate the Company`s stock price by disseminating materially false and misleading statements concerning its clinical trials of the drug sovaprevir. The Company falsely represented that sovaprevir, one of the protease inhibitor compounds in its portfolio of oral treatments for the hepatitis C virus, was well-tolerated and had a low potential for drug-drug interactions. Indeed, Achillion touted the results of its clinical tests even though, in July 2013, the United States Food and Drug Administration ("FDA") placed a clinical hold on sovaprevir after elevations in liver enzymes were noted in a phase 1 interaction study.  Full Article

US STOCKS-Wall St down on China, Greek worry; energy gains

* Indexes down: Dow 0.28 pct, S&P 0.12 pct, Nasdaq 0.02 pct (Updates to afternoon trade, commentary)

Search Stocks